Related Articles It’s Biopharma or Bust for the IPO Market Stephen Taub There Are Opportunities in Emerging Markets Outside AI — But Their Growth May Be Slow James Comtois Institutional Asset Owners are Rethinking ETFs Sponsored by Invesco